ArticleThe oncologist2026

Outcomes after SRS and ipilimumab plus nivolumab for melanoma brain metastases following prior immune checkpoint inhibitor or targeted therapy.

Ian Messing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.